SM-19712 hydrate
SIGMA/S3445 - ≥98% (HPLC)
Synonym: 4-
CAS Number: 194542-56-8 (anhydrous)
Empirical Formula (Hill Notation): C18H13ClN5NaO3S · xH2O
Molecular Weight: 437.84 (anhydrous basis)
MDL Number: MFCD06798351
Linear Formula: C18H13ClN5NaO3S · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | off-white to light brown |
| form | powder |
| InChI | 1S/C12H10ClN5O3S.Na.H2O/c |
| InChI key | HLHPDQXMLDUDQV-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | ClC1=CC=C(S(N(C(NC2=C(C#N |
| solubility | DMSO: ≥20 mg/mL |
| H2O: ≥20 mg/mL | |
| storage temp. | 2-8°C |
| Application: | SM-19712 hydrate was used in studies to determine the effectiveness of ECE inhibition as a treatment option for Alzheimer′s disease. |
| Biochem/physiol Actions: | Nonpeptide, potent and selective endothelin converting enzyme inhibitor. |
| Biochem/physiol Actions: | SM-19712 a sulfonylureid-pyrazole derivative is a potent and selective inhibitor of endothelin converting enzyme (ECE). It attenuates the effects of ischemic acute renal failure and reduces the inflammation, tissue injury and vasoconstriction induced by dextran sodium sulfate in mouse colon. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


